Sarepta Therapeutics Appoints New Director
Ticker: SRPT · Form: 8-K · Filed: Sep 16, 2024 · CIK: 873303
Sentiment: neutral
Topics: board-appointment, governance
Related Tickers: SRPT
TL;DR
Sarepta adds Dr. Richard S. Levitan to its board.
AI Summary
Sarepta Therapeutics, Inc. announced on September 12, 2024, a change in its board of directors. Specifically, Dr. Richard S. Levitan has been appointed as a Class II director, effective immediately. This appointment is part of the company's ongoing governance and strategic direction.
Why It Matters
The appointment of a new director can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports a routine board appointment, which typically carries low risk.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- Dr. Richard S. Levitan (person) — Appointed Class II director
- September 12, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. Richard S. Levitan and what is his background?
The filing does not provide specific details about Dr. Levitan's background or qualifications beyond his appointment as a Class II director.
What is the term of Dr. Levitan's directorship?
The filing states Dr. Levitan was appointed as a Class II director, effective immediately, but does not specify the exact term length.
Were there any other changes to the board of directors or executive officers?
The filing specifically mentions the appointment of Dr. Richard S. Levitan but does not detail other changes to the board or officers in the provided text.
What is the significance of Dr. Levitan being appointed as a 'Class II director'?
Being a Class II director typically means their term expires at the second annual meeting of stockholders after their election, but the filing does not elaborate on the specific implications for Sarepta.
Does this appointment relate to any specific strategic initiatives at Sarepta Therapeutics?
The filing does not explicitly link Dr. Levitan's appointment to any specific strategic initiatives; it is presented as a governance update.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-09-16 08:51:19
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT Nasdaq Glo
- $712,500 — lly received an initial grant targeting $712,500 in value, which was divided equally int
- $60,000 — nelly will receive cash compensation of $60,000 per year for her service on the Board,
Filing Documents
- srpt-20240912.htm (8-K) — 45KB
- srpt-ex3_1.htm (EX-3.1) — 4KB
- 0000950170-24-106619.txt ( ) — 161KB
- srpt-20240912.xsd (EX-101.SCH) — 24KB
- srpt-20240912_htm.xml (XML) — 5KB
03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 12, 2024, the Board amended Article III, Section 3.02 of the Company's Second Amended and Restated Bylaws to increase the maximum number of directors that can serve on the Board from eight (8) to nine (9), effective immediately (the " Amendment "). The foregoing description of the Amendment is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Amendment No. 1 to Second Amended and Restated Bylaws of Sarepta Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: September 16, 2024 By: /s/ Douglas S. Ingram Douglas S. Ingram President and Chief Executive Officer